These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 33639194)

  • 1. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease.
    Zhou H; Ma C; Wang C; Gong L; Zhang Y; Li Y
    Eur J Pharmacol; 2021 May; 898():173976. PubMed ID: 33639194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway.
    Chen M; Xing J; Pan D; Peng X; Gao P
    Biomed Pharmacother; 2020 Aug; 128():110286. PubMed ID: 32521450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
    Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
    J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα.
    Zhang M; Yuan Y; Wang Q; Li X; Men J; Lin M
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30291215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y; Chen L; Wang H; Narisi B; Chen B
    J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
    Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
    Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of herbs and active ingredients ameliorate non-alcoholic fatty liver disease under the guidance of traditional Chinese medicine.
    Zhou Z; Zhang J; You L; Wang T; Wang K; Wang L; Kong X; Gao Y; Sun X
    Front Endocrinol (Lausanne); 2022; 13():1000727. PubMed ID: 36204095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease.
    Liu C; Liao JZ; Li PY
    World J Gastroenterol; 2017 Mar; 23(11):1964-1973. PubMed ID: 28373762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
    Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
    World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c, PPAR-alpha and AMPK-alpha.
    Ren L; Sun D; Zhou X; Yang Y; Huang X; Li Y; Wang C; Li Y
    J Ethnopharmacol; 2019 Mar; 232():176-187. PubMed ID: 30590197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention and treatment of non-alcoholic fatty liver disease by regulation of mitochondrial function with Chinese medicine].
    Ma Q; Shi AH; Zhao X; Chen WL
    Zhongguo Zhong Yao Za Zhi; 2022 Oct; 47(19):5113-5120. PubMed ID: 36472018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of Fuzi Lizhong decoction in reducing liver injury of rats with non-alcoholic fatty liver via activating AMPK and suppressing NF-κBp65 pathway].
    Yang JY; Shi ZH; Ma W; Tao DQ; Liu S; Chen L; Zhou XL
    Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3176-3183. PubMed ID: 30200715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective Effect of Fuzi Lizhong Decoction against Non-alcoholic Fatty Liver Disease via Anti-inflammatory Response through Regulating p53 and PPARG Signaling.
    Yang J; Ma W; Mei Q; Song J; Shu L; Zhang S; Li C; An L; Du N; Shi Z
    Biol Pharm Bull; 2020; 43(11):1626-1633. PubMed ID: 33132309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
    Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
    Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gentiopicroside Ameliorates Oxidative Stress and Lipid Accumulation through Nuclear Factor Erythroid 2-Related Factor 2 Activation.
    Jin M; Feng H; Wang Y; Yan S; Shen B; Li Z; Qin H; Wang Q; Li J; Liu G
    Oxid Med Cell Longev; 2020; 2020():2940746. PubMed ID: 32655764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the mechanism of PingTang No.5 capsule on nonalcoholic fatty liver disease through network pharmacology and experimental validation.
    Hung TC; Zhao N; Huang C; Liu S; Liu T; Huang W; Xu X; Ji ZL; Yang S
    Biomed Pharmacother; 2021 Jun; 138():111408. PubMed ID: 33684693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chinese herbal medicines: The modulator of nonalcoholic fatty liver disease targeting oxidative stress.
    Gong P; Long H; Guo Y; Wang Z; Yao W; Wang J; Yang W; Li N; Xie J; Chen F
    J Ethnopharmacol; 2024 Jan; 318(Pt B):116927. PubMed ID: 37532073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jiang-Zhi granules decrease sensitivity to low-dose CCl
    Yang L; Zhou Y; Song H; Zheng P
    BMC Complement Altern Med; 2019 Aug; 19(1):228. PubMed ID: 31438932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.